FUSAROLI, MICHELE

FUSAROLI, MICHELE  

DIPARTIMENTO DI SCIENZE MEDICHE E CHIRURGICHE  

Dottorandi  

Mostra records
Risultati 1 - 20 di 38 (tempo di esecuzione: 0.061 secondi).
Titolo Autore(i) Anno Periodico Editore Tipo File
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS Fusaroli M.; Giunchi V.; Battini V.; Puligheddu S.; Khouri C.; Carnovale C.; Raschi E.; Poluzzi E. 2024-01-01 DRUG SAFETY - 1.01 Articolo in rivista s40264-023-01391-4.pdf40264_2023_1391_MOESM1_ESM.docx
Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database Pauline O.; Robert M.; Bernardeau C.; Hlavaty A.; Fusaroli M.; Roustit M.; Cracowski J.L.; Khouri C. 2023-01-01 BIODRUGS - 1.01 Articolo in rivista -
Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the ‘impulse control disorders’ diagnostic construct Fusaroli M.; Pellegrini L.; Fusaroli R.; Raschi E.; Menchetti M.; Poluzzi E. 2023-01-01 ADDICTION - 1.01 Articolo in rivista Behavioral excess and disruptive conduct A historical and taxonomic approach to the origin of the 'impulse control disorders' diagnostic construct.pdf
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors Sisi, Monia; Vitale, Giovanni; Fusaroli, Michele; Riefolo, Mattia; Giunchi, Valentina; D’Errico, ...Antonietta; Ardizzoni, Andrea; Raschi, Emanuel; Gelsomino, Francesco 2023-01-01 JTO CLINICAL AND RESEARCH REPORTS - 1.01 Articolo in rivista Sisi et al. JTO CCR 23.pdfSisi et al. JTO CCR supplementary 23.pdf
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians Raschi, Emanuel; Rossi, Simone; De Giglio, Andrea; Fusaroli, Michele; Burgazzi, Flavio; Rinaldi, ...Rita; Potena, Luciano 2023-01-01 DRUG SAFETY - 1.01 Articolo in rivista Raschi et al., Drug Safety Cardiotoxicity ICI 2023.pdf40264_2023_1320_MOESM1_ESM.pdf
Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach Giunchi, Valentina; Fusaroli, Michele; Hauben, Manfred; Raschi, Emanuel; Poluzzi, Elisabetta 2023-01-01 DRUG SAFETY - 1.01 Articolo in rivista -
Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System Fusaroli M.; Pelletti G.; Giunchi V.; Pugliese C.; Bartolucci M.; Necibi E.N.; Raschi E.; De Pont...i F.; Pelotti S.; Poluzzi E. 2023-01-01 DRUG SAFETY - 1.01 Articolo in rivista s40264-022-01269-x.pdf40264_2022_1269_MOESM1_ESM.pdf
Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study Fusaroli M.; Giunchi V.; Battini V.; Gringeri M.; Rimondini R.; Menchetti M.; Radice S.; Pozzi M....; Nobile M.; Clementi E.; De Ponti F.; Carnovale C.; Raschi E.; Poluzzi E. 2023-01-01 PSYCHIATRY AND CLINICAL NEUROSCIENCES - 1.01 Articolo in rivista Exploring the underlying mechanisms of drug-induced impulse control disorders a pharmacovigilance-pharmacodynamic study.pdf
Identifying Medications Underlying Communication Atypicalities in Psychotic and Affective Disorders: A Pharmacovigilance Study Within the FDA Adverse Event Reporting System Fusaroli M.; Simonsen A.; Borrie S.A.; Low D.M.; Parola A.; Raschi E.; Poluzzi E.; Fusaroli R. 2023-01-01 JOURNAL OF SPEECH, LANGUAGE, AND HEARING RESEARCH - 1.01 Articolo in rivista 2022.09.05.22279609v3.full.pdf
Interpretation of Pharmacovigilance Disproportionality Analyses Khouri, Charles; Fusaroli, Michele; Salvo, Francesco; Raschi, Emanuel 2023-01-01 CLINICAL PHARMACOLOGY & THERAPEUTICS - 1.04 Replica / breve intervento (e simili) -
Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study Fusaroli M.; Salvo F.; Bernardeau C.; Idris M.; Dolladille C.; Pariente A.; Poluzzi E.; Raschi E....; Khouri C. 2023-01-01 DRUG SAFETY - 1.01 Articolo in rivista Fusaroli_2023.pdf40264_2023_1329_MOESM2_ESM.xlsx40264_2023_1329_MOESM1_ESM.pdf
The environmental impact of pharmaceuticals in Italy: Integrating healthcare and eco-toxicological data to assess and potentially mitigate their diffusion to water supplies Giunchi V.; Fusaroli M.; Linder E.; Villén J.; Wettermark B.; Nekoro M.; Raschi E.; Lunghi C.; Po...luzzi E. 2023-01-01 BRITISH JOURNAL OF CLINICAL PHARMACOLOGY - 1.01 Articolo in rivista Brit J Clinical Pharma - 2023 - Giunchi - The environmental impact of pharmaceuticals in Italy Integrating healthcare and.pdf15761.zip
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System Raschi E.; Fusaroli M.; Giunchi V.; Repaci A.; Pelusi C.; Mollica V.; Massari F.; Ardizzoni A.; P...oluzzi E.; Pagotto U.; Di Dalmazi G. 2022-01-01 CANCERS - 1.01 Articolo in rivista cancers-14-04610-v2 (2).pdf
Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System Gaimari A.; Fusaroli M.; Raschi E.; Baldin E.; Vignatelli L.; Nonino F.; De Ponti F.; Mandrioli J....; Poluzzi E. 2022-01-01 DRUG SAFETY - 1.01 Articolo in rivista Amyotrophic.pdf
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems Gatti M.; Fusaroli M.; Raschi E.; Capelli I.; Poluzzi E.; De Ponti F. 2022-01-01 JN. JOURNAL OF NEPHROLOGY - 1.01 Articolo in rivista 40620_2021_1191_MOESM2_ESM.pptx40620_2021_1191_MOESM1_ESM.pptx
Immune Checkpoint Inhibitors and Pregnancy: Analysis of the VigiBase® Spontaneous Reporting System Noseda, Roberta; Müller, Laura; Bedussi, Francesca; Fusaroli, Michele; Raschi, Emanuel; Ceschi, A...lessandro 2022-01-01 CANCERS - 1.01 Articolo in rivista 157_ICI_Pregnancy_Cancers_2023.pdfcancers-15-00173-s001.zip
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System Fusaroli M.; Raschi E.; Giunchi V.; Menchetti M.; Rimondini Giorgini R.; De Ponti F.; Poluzzi E. 2022-01-01 INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY - 1.01 Articolo in rivista pyac031-10.pdfpyac031_suppl_supplementary_material.pdf
Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal Raschi, Emanuel; Fusaroli, Michele; Gatti, Milo; Caraceni, Paolo; Poluzzi, Elisabetta; De Ponti, ...Fabrizio 2022-01-01 PHARMACEUTICALS - 1.01 Articolo in rivista 144_DILI_Nintedanib_Pharmaceuticals_2022.pdf
Post-marketing safety profile of cannabis products: Signals from the FDA adverse event reporting system Giunchi, V; Fusaroli, M; Lunghi, C; Zongo, A; Raschi, E; Poluzzi, E 2022-01-01 PHARMACOEPIDEMIOLOGY AND DRUG SAFETY - 1.06 Abstract in rivista -
Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database Fusaroli M.; Isgro V.; Cutroneo P.M.; Ferrajolo C.; Cirillo V.; Del Bufalo F.; Raschi E.; Poluzzi... E.; Trifiro G. 2022-01-01 DRUG SAFETY - 1.01 Articolo in rivista s40264-022-01194-z-2.pdf40264_2022_1194_MOESM1_ESM.docx